Table 2 Comparison of clinical features in patients with complete, partial, and no remission after tacrolimus treatment

Age

40 ± 16

38 ± 16

37 ± 15

0.31

Gender (Female %)

21.2%

21.6%

45.3%

<0.001

eGFR (mL/min/1.73 m²)

100 ± 28

107 ± 23

111 ± 22

0.008

eGFR < 60 mL/min/1.73 m²

6.6%

2.3%

2.1%

0.11

Proteinuria, g/24 h

6.4 (4.7–8.4)

6.1(4.8–7.9)

5.9 (4.7–7.4)

0.37

Serum albumin (g/L)

24.2 ± 3.4

24.7 ± 3.3

24.8 ± 3.4

0.30

Previous treatment with immunosuppressive drugs

26.3%

14.7

9.5%

0.002

Combined with RASi treatment

68.6%

71.5%

66.3%

0.65

Combined with corticosteroids

90.5%

94.9%

96.8%

0.11

Tacrolimus treatment since onset of disease (months)

7.6 (3.9–14.8)

7.3 (2.9–13.3)

5.1 (2.1–9.5)

0.001

Tacrolimus exposure (ng/mL)

4.2 ± 2.0

4.7 ± 2.1

5.2 ± 2.2

0.002